{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:17:55Z","timestamp":1778102275197,"version":"3.51.4"},"reference-count":5,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2020.09.027","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T09:50:42Z","timestamp":1599817842000},"page":"981-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stevens-Johnson syndrome and toxic epidermal necrolysis reactions to BRAF and MEK inhibitors in patients with melanoma: A systematic review"],"prefix":"10.1016","volume":"85","author":[{"given":"Yuliya","family":"Lytvyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muskaan","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalad","family":"Maliyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.09.027_bib1","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/cancers12061650","article-title":"Safety of BRAF+MEK inhibitor combinations: severe adverse event evaluation","volume":"12","author":"Meirson","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaad.2020.09.027_bib2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.027_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/CMR.0b013e3283573437","article-title":"Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib","volume":"22","author":"Minor","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2020.09.027_bib4","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/jdv.14010","article-title":"Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure","volume":"31","author":"Arenbergerova","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.027_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncologist"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222032613X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222032613X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:54Z","timestamp":1759273314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222032613X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S019096222032613X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens-Johnson syndrome and toxic epidermal necrolysis reactions to BRAF and MEK inhibitors in patients with melanoma: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}